Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement
2009年4月8日 - 4:00AM
ビジãƒã‚¹ãƒ¯ã‚¤ãƒ¤ï¼ˆè‹±èªžï¼‰
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in
compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the
independent audit report included in the Company�s Annual Report on
Form 10-K for the fiscal year ended December 31, 2008 contained an
unqualified audit opinion from its independent public accounting
firm, Ernst & Young LLP, which included a �going concern�
explanatory statement. This disclosure is required under NASDAQ
rules and does not represent any change to the Company�s Annual
Report on Form 10-K for the year ended December 31, 2008 which was
filed on March 31, 2009 with the Securities and Exchange
Commission.
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class cancer
therapeutics.
Avalon (NASDAQ:AVRX)
éŽåŽ» æ ªä¾¡ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 5 2024 ã¾ã§ 6 2024
Avalon (NASDAQ:AVRX)
éŽåŽ» æ ªä¾¡ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 6 2023 ã¾ã§ 6 2024
Real-Time news about Avalon Pharmaceuticals (MM) (ãƒŠã‚¹ãƒ€ãƒƒã‚¯å¸‚å ´): 0 recent articles
ãã®ä»–ã®Avalon Pharmaceuticals, Inc.ニュース記事